Replies to post #423756 on Anavex Life Sciences Corp (AVXL)

[bas2020]

"...can delay by 22.3%" is like saying "might". I doubt that 22.3% is even perceptible, but the SAEs would surely be. The article is a huge exaggeration and over hype of the results.

In contrast, the "might" that blarcamesine offers is IMPROVEMENT, w/o SAEs, i.e. "disease modifying".

[Schmiggins]

Thanks. This paragraph was interesting. Imagine if Anavex had done this! First time I heard anyone mention it in the glowing press reports:

"Some critics suggest that the reliance on “slowing of disease” in data around monoclonal antibodies is meant to mask unconvincing raw data – it is unclear whether a 2.92-point difference in iARDS rating at the 18-month mark will produce a clinically meaningful difference. The iARDS scale itself is an Eli Lilly creation and the only assessment of clinically significant differences on the scale was authored by Eli Lilly researchers."

!!!!!!